<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01240213</url>
  </required_header>
  <id_info>
    <org_study_id>SAC110024</org_study_id>
    <secondary_id>IR 7297</secondary_id>
    <nct_id>NCT01240213</nct_id>
  </id_info>
  <brief_title>Vitamin D, Diet and Activity Study</brief_title>
  <acronym>ViDA</acronym>
  <official_title>Vitamin D, Weight Loss, and Breast Cancer Biomarkers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Experimental and human data suggests that vitamin D could protect against breast cancer.&#xD;
      Overweight/obese individuals are at increased risk of low vitamin D levels. Vitamin D may&#xD;
      reduce production of fat tissue, thereby reducing weight gain, which would result in lower&#xD;
      levels of adipose-derived hormones and other breast cancer risk factors.The purpose of this&#xD;
      study is to test the effect of vitamin D supplementation on the response to a weight loss&#xD;
      (diet + exercise) intervention and select breast cancer risk factors in overweight and obese&#xD;
      postmenopausal women with low blood vitamin D levels.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Objective: To test the incremental effect of vitamin D supplementation (2000 IU/day) in 228&#xD;
      overweight and obese postmenopausal women with low blood vitamin D levels on response to a&#xD;
      weight loss (diet + exercise) intervention in a double-blind placebo-controlled clinical&#xD;
      trial.&#xD;
&#xD;
      Primary Aim:&#xD;
&#xD;
      • Determine the effects of 12-months vitamin D supplementation vs. placebo on weight loss in&#xD;
      women following a weight loss diet and exercise program.&#xD;
&#xD;
      Secondary Aims:&#xD;
&#xD;
        -  Determine the effects of 12-months vitamin D vs. placebo on blood biomarkers associated&#xD;
           with increased breast cancer risk (insulin, glucose, CRP).&#xD;
&#xD;
        -  Test 12-months vitamin D effects on muscle strength as measured by 1RM leg press and&#xD;
           bench press in women undergoing weight loss.&#xD;
&#xD;
        -  Test the effect of 12-month vitamin D supplementation on effects on quality of life&#xD;
           (QOL) in women undergoing weight loss.&#xD;
&#xD;
      Additional Aims:&#xD;
&#xD;
        -  In a 50% subset of women, test the effect of 12-month vitamin D supplementation vs.&#xD;
           placebo on breast epithelial cell cytomorphology (quantified by the Masood cytology&#xD;
           index) obtained through random periareolar fine needle aspiration (RPFNA).&#xD;
&#xD;
        -  Collect subcutaneous abdominal fat aspirations in the 50% subsample of women.&#xD;
&#xD;
      OUTLINE: This is a randomized study. Participants are stratified according to body mass index&#xD;
      (&lt; 30 vs ≥ 30) and RPFNA-consent. All participants will receive a 6-month weight loss&#xD;
      intervention (prescribed weight loss goal of 10% of initial body weight) followed by 6&#xD;
      months' maintenance therapy.&#xD;
&#xD;
      Baseline, 6-, and 12-month measurements will include weight, BMI, waist and hip&#xD;
      circumference, serum 25-hydroxyvitamin D, fasting blood samples, and questionnaires on&#xD;
      details of diet especially items containing vitamin D, physical activity levels, sun exposure&#xD;
      including clothing and sunscreen habits, dietary supplement and vitamin use, and medications.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>October 2010</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">August 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Compare the effects of a 1-year one year Vitamin D supplementation vs placebo, on weight loss in postmenopausal women following a weight loss diet and exercise program.</measure>
    <time_frame>One Year</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the effects of 12-months vitamin D vs. placebo on blood biomarkers (insulin,glucose,CRP) associated with increased breast cancer risk.</measure>
    <time_frame>One Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Test 12-months vitamin D effects on muscle strength as measured by 1RM leg press and bench press in women undergoing weight loss.</measure>
    <time_frame>One Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Test the effect of 12-month vitamin D supplementation on effects on quality of life (QOL) in women undergoing weight loss.</measure>
    <time_frame>One Year</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Vitamin D supplementation on breast epithelial cell cytomorphology</measure>
    <time_frame>One Year</time_frame>
    <description>In a 50% subset of women, test the effect of 12-month vitamin D supplementation vs. placebo on breast epithelial cell cytomorphology (quantified by the Masood cytology index) obtained through random periareolar fine needle aspiration (RPFNA).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Effect of Vitamin D on epithelial cell gene expression</measure>
    <time_frame>One year</time_frame>
    <description>In a 50% subset of women, test the effect of 12-month vitamin D supplementation vs. placebo on breast epithelial cell gene expression as measured by qRT-PCR. The breast epithelial cells are collected by RPFNA</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">218</enrollment>
  <condition>Breast Cancer</condition>
  <condition>Obesity</condition>
  <condition>Hypovitaminosis D</condition>
  <arm_group>
    <arm_group_label>Vitamin D</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>2000 IU per day of Vitamin D</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Vitamin D</intervention_name>
    <description>2000 IU per day of Vitamin D</description>
    <arm_group_label>Vitamin D</arm_group_label>
    <other_name>calciferol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>1 Placebo per day</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Sugar pill</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 50-75 years&#xD;
&#xD;
          -  Postmenopausal (no periods for past 12 months)&#xD;
&#xD;
          -  Screening serum vitamin D (25(OH)D) between 10 and 32 ng/mL (&quot;insufficient&quot;)&#xD;
&#xD;
          -  No menopausal HRT use of any type including vaginal X 6 months and willing to avoid&#xD;
             use for study duration&#xD;
&#xD;
          -  BMI &gt; 25.0 kg/m2 (&gt; 23.0 for Asians)&#xD;
&#xD;
          -  Physically able to undertake a calorie reduction and exercise program&#xD;
&#xD;
          -  Able to come for clinic visits, classes, and measurements, fill out questionnaires and&#xD;
             logs in English&#xD;
&#xD;
          -  Gives informed consent, agrees to be randomly assigned&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Currently using more that 400 IU vitamin D from supplemental sources&#xD;
&#xD;
          -  Screening vitamin D level &lt; 10 ng/mL (will be referred to primary provider) or &gt; 32&#xD;
             ng/mL (already sufficient)&#xD;
&#xD;
          -  Osteoporosis&#xD;
&#xD;
          -  Renal disease, history of kidney stones&#xD;
&#xD;
          -  Any contra-indications to taking vitamin D 2000 IU/day&#xD;
&#xD;
          -  Plans to leave the study area within the follow-up period&#xD;
&#xD;
          -  Plans to join another organized weight loss program or take appetite suppressant&#xD;
             medication during the study period&#xD;
&#xD;
          -  History of bariatric surgery&#xD;
&#xD;
          -  Current use of medications likely to interfere with adherence to interventions or&#xD;
             study outcomes&#xD;
&#xD;
          -  Current smoker&#xD;
&#xD;
          -  Personal history of invasive or in situ breast cancer&#xD;
&#xD;
          -  Personal history of invasive cancer other than breast: except for non- melanoma skin&#xD;
             cancer which would be eligible&#xD;
&#xD;
          -  Diabetes mellitus&#xD;
&#xD;
          -  Abnormalities on screening physical that contraindicate participation&#xD;
&#xD;
          -  Severe congestive heart failure per NYHA criteria 3 &amp; 4&#xD;
&#xD;
          -  Contraindications for entry into a research exercise program: recent (within 6 months)&#xD;
             myocardial infarction, pulmonary edema, myocarditis, pericarditis, unstable angina,&#xD;
             pulmonary embolism, deep vein thrombosis, uncontrolled hypertension (systolic &gt; 200,&#xD;
             diastolic &gt; 100), orthostatic hypotension, moderate/severe aortic stenosis,&#xD;
             uncontrolled arrythmia, uncontrolled congestive heart failure, left bundle branch&#xD;
             block, history of cardiac arrest or stroke&#xD;
&#xD;
          -  Alcohol or drug abuse, significant mental illness (as assessed by study staff&#xD;
             impression)&#xD;
&#xD;
          -  For the RPFNA/adipose tissue substudy: bilateral breast cancer, bilateral mastectomy,&#xD;
             unable or unwilling to stop aspirin or NSAIDs for 1 week before and after the&#xD;
             procedure, allergy to anesthetics or local anesthetics.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Anne McTiernan, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutchinson Cancer Research Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fred Hutchinson Cancer Research Center</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <study_first_submitted>November 9, 2010</study_first_submitted>
  <study_first_submitted_qc>November 10, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 15, 2010</study_first_posted>
  <last_update_submitted>August 5, 2013</last_update_submitted>
  <last_update_submitted_qc>August 5, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 7, 2013</last_update_posted>
  <responsible_party>
    <name_title>Anne McTiernan, MD PhD</name_title>
    <organization>FHCRC</organization>
  </responsible_party>
  <keyword>Vitamin D</keyword>
  <keyword>lifestyle intervention</keyword>
  <keyword>postmenopausal women</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Rickets</mesh_term>
    <mesh_term>Avitaminosis</mesh_term>
    <mesh_term>Vitamin D Deficiency</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vitamin D</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

